Explorez tous les épisodes de CCO Infectious Disease Podcast
Plongez dans la liste complète des épisodes de CCO Infectious Disease Podcast. Chaque épisode est catalogué accompagné de descriptions détaillées, ce qui facilite la recherche et l'exploration de sujets spécifiques. Suivez tous les épisodes de votre podcast préféré et ne manquez aucun contenu pertinent.
Rows per page:
50
1–50 of 431
Date
Titre
Durée
17 Feb 2023
Perspectives From Latin America on Advances in HIV PrEP
00:22:27
In this episode, 2 HIV experts from Latin America share their thoughts on the current status of HIV prevention strategies in the region, including recent successes and ongoing challenges. Specifically, the faculty discuss:
Barriers that limit PrEP availability in many regions of Latin America despite the high need among vulnerable and at-risk groups
Successful expansion of PrEP access in Brazil
Key findings from the prospective ImPrEP study evaluating implementation of same-day oral PrEP among men who have sex with men and transgender women in Brazil, Mexico, and Peru
What long-acting PrEP could mean for at-risk groups in Latin America when it becomes available
Important considerations for PrEP among TGW
Presenters:
Claudia P. Cortes MD Associate Professor Infectious Diseases Universidad de Chile Santiago, Chile
Beatriz Grinsztejn MD, PhD Diretora, STD/HIV Clinical Research Laboratory Instituto Nacional de Infectologia Evandro Chagas Oswaldo Cruz Foundation Rio de Janeiro, Brazil
Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.
Adult HBV Vaccination: Identifying Individuals at Risk for Reduced Seroprotection
00:10:32
In this episode, learn about the importance of identifying adults at risk for reduced hepatitis B virus (HBV) seroprotection and applying current HBV vaccine recommendations in special populations. Listen as Robert G. Gish, MD, discusses key information on the identification and evaluation of patients who have chronic health conditions and therefore may be at risk for nonresponse to available vaccines.
Presenter:
Robert G. Gish, MD Professor of Medicine Loma Linda University Loma Linda, California Adjunct Professor of Medicine Nevada School of Medicine Las Vega, Nevada Clinical Professor University of Nevada Reno School of Medicine Reno, Nevada Clinical Professor University of California Skaggs School of Pharmacy and Pharmaceutical Sciences San Diego, California Medical Director Hepatitis B Foundation Washington, DC
Hepatitis B Reactivation: Patient and Physician Sharing Session #4
00:24:06
In episode 4 of an ongoing series of sharing sessions between a physician and patient, Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, discusses hepatitis B diagnosis and treatment with his patient, Mark. The conversation focuses on Mark’s missed HBV diagnosis and likely reactivation following treatment for rheumatoid arthritis and raises awareness for needed improvements to communication between multidisciplinary healthcare teams.
Presenter:
Geoffrey M. Dusheiko MD, FCP(SA), FRCP Emeritus Professor of Medicine University College London School of Medicine Kings College Hospital London, United Kingdom
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Conference Conversations: HIV Advanced Practice Provider Perspectives from CROI 2022
00:18:10
In this episode, Jeffrey Kwong, DNP, MPH, FAANP, FAAN, and Susan LeLacheur, DrPH, PA-C, AAHIVS, share insights on new HIV data from CROI 2022, including:
Perinatal antiretroviral therapy exposure
Investigational formulation of long-acting contraception combined with pre-exposure prophylaxis
Monitoring with long-acting cabotegravir for pre-exposure prophylaxis
Myocardial infarction risk by HIV status
Presenters:
Jeffrey Kwong, DNP, MPH, FAANP, FAAN Professor Division of Advanced Nursing Practice Rutgers School of Nursing Newark, New Jersey Nurse Practitioner Gotham Medical Group New York, New York
Susan LeLacheur, DrPH, PA-C, AAHIVS Professor PA Studies The George Washington University School of Medicine and Health Sciences Washington, DC
Shingles in the COVID-19 Era: Increasing Shingles Vaccine Uptake—Audio Recap
00:17:49
In this episode, Dalilah Restrepo, MD, discusses barriers to shingles vaccination and strategies to increase routine vaccine uptake in the COVID-19 era.
Using the latest data and expert guidance, this podcast covers topics such as:
Shingles disease burden and increasing incidence over time
Decline in shingles vaccination rates in the COVID-19 era
National Vaccine Advisory Committee standards of care
CDC guidance catching up after RZV dosing delays
Strategies to increase shingles vaccine uptake
Presenter:
Dalilah Restrepo, MD Infectious Diseases Specialist Fountain Valley Hospital Fountain Valley, California
Content based on a CME program supported by an educational grant from GlaxoSmithKline
My Management Strategies for NASH in Patients With HIV
00:06:43
In this episode, Mark S. Sulkowski, MD, discusses his recommended approach for managing nonalcoholic steatohepatitis in patients with HIV, including recognizing nonalcoholic steatohepatitis, recommending lifestyle interventions, and considering pharmacologic approaches.
Presenter:
Mark S. Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Chief, Infectious Disease Johns Hopkins Bayview Medical Center Johns Hopkins University School of Medicine Baltimore, Maryland
Content based on an online CME program supported by an educational grant from Theratechnologies Inc.
Where We Want to Be: The Search for a Cure for HIV
00:52:41
In this third of 3 episodes, global HIV experts and advocates discuss the current status of HIV cure research, including key concepts to understand and communicate when counselling patients, colleagues, and the broader community on HIV cure:
Latest understanding of the viral reservoir
New insights and questions on the best timing for cure interventions
Current investigational strategies showing promise
Ethical considerations related to participant education, representation in clinical trials, and planning for broad global access
Faculty:
Katharine J. Bar, MD Associate Professor of Medicine Director, Penn CFAR Virus and Reservoirs Core University of Pennsylvania Philadelphia, Pennsylvania
Jennifer Blanchette, PhD Independent Contractor Clinical Care Options Colorado, United States
Krista L. Dong, MD Clinical Director, FRESH Cohort Assistant Professor of Medicine Massachusetts General Hospital Harvard Medical School Boston, Massachusetts
Karine Dubé, DrPH, MPhil Associate Professor UCSD School of Medicine Division of Infectious Diseases and Global Public Health San Diego, California
Richard Jefferys Basic Science, Vaccines & Cure Project Director Treatment Action Group New York, New York
Sharon R. Lewin, AO, FRACP, PhD, FAA, FAHMS Director Doherty Institute Melbourne Laureate Professor and Head Department of Infectious Diseases The University of Melbourne Consultant Physician Victorian Infectious Diseases Service Royal Melbourne Hospital Consultant Physician and Adjunct Professor Department of Infectious Diseases Alfred Hospital and Monash University Melbourne, Australia
Angelina Namiba Founder Member 4M Network of Mentor Mothers London, United Kingdom
Finding Our Voices: Older Women With HIV in Resource-Limited Settings
00:17:52
In this episode, listen to Dorothy Onyango, patient and patient activist, share her views on the many barriers encountered by aging patients with HIV living in resource-limited settings and the need to work on solutions to overcome such barriers, including:
The major burden of poverty affecting access to care/medications, healthcare services (eg, treatment for noncommunicable diseases, home-based care), and social support
The added social obstructions to HIV care for older women (eg, sexual reproductive health rights)
Potential solutions to support the aging population with HIV to encourage good health and wellness such as:
Self-advocacy to provide a voice for patients, especially women
A comprehensive public health response
Policy changes, including a budget line in the national budget, to ensure the rights of older people
Income-generating activities to help older patients with HIV become economically sound
Faculty:
Dorothy Onyango Chief Executive Officer Women Fighting AIDS in Kenya Founding Member, International Community of Women Living With HIV Former Chair, Pan African Women’s Coalition Former Board Member, Kenya National AIDS Council Nairobi, Kenya
Using common case scenarios, Robert H. Hopkins, Jr., MD, MACP, and Laura P. Hurley, MD, MPH, discuss strategies for optimizing shingles vaccine uptake, including:
The pathophysiology of shingles to better understand risk and burden
CDC guidelines and ACIP shingles vaccine recommendations, including considerations for those who are immunocompromised
Strategies for optimizing shingles vaccine uptake no matter the clinical setting
How to address shingles vaccine‒related adverse events
Addressing insurance-related concerns
Presenters:
Robert H. Hopkins, Jr., MD, MACP Professor of Internal Medicine and Pediatrics Chief, Division of General Internal Medicine University of Arkansas for Medical Sciences School of Medicine Little Rock, Arkansas
Laura P. Hurley, MD, MPH General Internist and Health Services Researcher Associate Professor of Medicine Department of General Internal Medicine University of Colorado Anschutz Medical Campus Aurora, Colorado
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
27 Sep 2023
Q&A on HIV PrEP: Episode 2 on Cisgender Women
00:32:03
In this episode, Oni Blackstock, MD, MHS, and Whitney Irie, MSW, PhD, discuss key considerations for PrEP uptake in cisgender women, including:
Ways to perform a nonintimidating sexual history
How to incorporate conversations on PrEP during a short clinic visit
Discussing adverse events associated with PrEP options with patients
Considerations for PrEP in women wanting to conceive
How patients can navigate obtaining PrEP in areas with limited healthcare resources
Guideline recommendation updates on PrEP eligibility
Use of wrap-around services
Interventions to improve PrEP access (eg, telehealth, nurse-led PrEP)
Faculty
Oni Blackstock, MD, MHS Founder & Executive Director Health Justice New York, New York
Whitney Irie, MSW, PhD Assistant Professor Department of Social Work Boston College Brighton, Massachusetts
Link to full program: https://bit.ly/3PZGYdR
24 Dec 2020
Ending the HIV Epidemic: Strategies for Preventing New Infections
00:37:03
In this episode, the third in a 3-part series on Ending the HIV Epidemic, Judith Feinberg, MD, and Kenneth Mayer, MD, discuss the important role of HIV pre-expsoure prophylaxis (PrEP) for preventing HIV infection among at-risk individuals and critical strategies for effective PrEP implementation among principle populations, including men who have sex with men and transgender women, heterosexual cisgender women, and people who inject drugs. Following their dialogue, the faculty field clinician questions on HIV prevention.
Presenters:
Judith Feinberg, MD Professor Attending Physician Departments of Medicine and Behavioral Medicine & Psychiatry West Virginia University School of Medicine Morgantown, West Virginia
Kenneth Mayer, MD Infectious Disease Attending Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School Medical Research Director Fenway Community Health Boston, Massachusetts
Content based on an online CME program supported by educational grants from Gilead Sciences and ViiV Healthcare and produced in collaboration with PCE and HealthHIV.
Switching to Long-Acting Cabotegravir Plus Rilpirivine for HIV Treatment: Assessing Candidacy and Patient Counseling
00:17:19
In this episode, an international expert panel shares their thoughts on key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, including selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience. Subsequent episodes in this 4-part series will cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including operational planning, clinic impact, and handling missed doses with long-acting antiretroviral therapy for treatment; long-acting HIV pre-exposure prophylaxis; and what is still needed in long-acting HIV care to further address patient needs and inequities across subgroups.
Presenters:
Babafemi Taiwo, MBBS Gene Stollerman Professor of Medicine Chief, Division of Infectious Diseases Northwestern University Feinberg School of Medicine Chicago, Illinois
Yvonne Gilleece, MB, BCh, BAO Honorary Clinical Professor in HIV Medicine and Sexual Health Department of Global Health & HIV Brighton & Sussex Medical School Consultant in HIV Medicine and Sexual Health HIV Department University Hospitals Sussex NHS Foundation Trust Brighton, United Kingdom
Cristina Mussini, MD Head of Department of Infectious Diseases and Tropical Medicine Full Professor of Infectious Diseases Infectious Diseases Clinics, University Hospital University of Modena and Reggio Emilia Modena, Italy
Darrell H. S. Tan, MD, FRCPC, PhD Associate Professor Division of Infectious Diseases University of Toronto Clinician-Scientist Division of Infectious Diseases St. Michael's Hospital Toronto, Canada
Content based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare.
Unlocking the Promise of PrEP and the Future of PrEP
00:45:49
In this episode, global PrEP experts and advocates discuss barriers that have prevented the full potential of today’s PrEP regimens from being delivered, how those barriers might be overcome, and how the next generation of PrEP modalities may address unmet needs, including:
How access and implementation of PrEP have limited its benefit and led to disparities in uptake among racial and ethnic groups in the United States and among key populations globally
The challenges of adherence to PrEP for healthy individuals who are required to consistently take medication and engage with the healthcare system when they aren’t sick
The potential for longer-acting PrEP modalities and a greater number of PrEP options for individuals in the future to expand PrEP uptake and adherence with equitable global access
Faculty:
Jessica L. Adams, PharmD, AAHIVE Scientific Director, Infectious Diseases Clinical Care Options New York, United States
Linda-Gail Bekker, MBChB, DCH, DTM&H, FCP(SA), PhD Professor and Director The Desmond Tutu HIV Centre University of Cape Town South Africa Chief Executive Officer The Desmond Tutu Health Foundation Cape Town, South Africa
Kenyon R. Farrow PrEP Advocate Vice President of Policy Point Source Youth Contributing Editor TheBody.com Ohio, United States
Beatriz Grinsztejn, MD, PhD Director STI/AIDS Clinical Research Laboratory Instituto Nacional de Infectologia Evandro Chagas-Fiocruz Rio de Janeiro, Brazil
Brittany Williams, PhD PrEP Advocate Assistant Professor of Higher Education and Student Affairs Administration Department of Education University of Vermont Vermont, United States
In this episode, Tatyana Kushner, MD, MSCE, and Stefan Zeuzem, MD, address key considerations when screening, diagnosing, and treating patients with HDV, such as:
Barriers to HDV screening, including limitations to AASLD guideline recommendations
Use of double reflex testing to improve HDV diagnosis
Considerations for repeat HDV testing in patients who are HBsAg positive who previously tested negative for HDV
Updated CDC recommendations for HBV screening for all adults using a triple panel test
Staging advanced liver disease in patients with HDV
Indications for HDV treatment, including patients with low ALT levels and advanced or progressive liver disease
Treatment landscape for HDV
Personal experiences with use of pegylated interferon for HDV treatment, including considerations for use in patients with compensated cirrhosis
Updates on novel HDV therapies, including:
Summary of efficacy data on bulevirtide from clinical trials
Interpretation of results from D-LIVR, a phase III trial assessing the safety and efficacy of lonafarnib
Empowering Patients With Education on HBV: Sharing Session 2
00:16:49
In this episode, Robert Wong, MD, MS, and a patient discuss opportunities to optimize care for people living with hepatitis B virus (HBV), including:
Opportunities to improve patient education, including education for expectant mothers with HBV
Potential cultural considerations that may result in delayed HBV diagnosis and care
Stigma reduction with universal HBV screening and vaccination
Strategies to improve patient education (eg, online resources, advocacy groups, use of layman’s terms and diagrams, repetition)
Presenter:
Robert Wong, MD, MS Clinical Associate Professor Division of Gastroenterology and Hepatology Stanford University School of Medicine Palo Alto, California
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
14 Oct 2021
New COVID-19 Data: A Case for Optimism?
00:42:18
In this podcast episode, Paul E. Sax, MD, and Renslow Sherer, MD, discuss the clinical significance of new data on the prevention and treatment of COVID-19, including:
COVID-19 in immunocompromised hosts
Prime-Boost Strategy for COVID-19 vaccination
COVID-19 surge effects
Monoclonal antibody therapy for prevention and treatment
Remdesivir update
Repurposed drug, fluvoxamine
What does the future of the pandemic look like?
Presenters:
Paul E. Sax, MD Clinical Director HIV Program and Division of Infectious Diseases Brigham and Women's Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts
Renslow Sherer, MD Director International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois
In this episode, Oni Blackstock, MD, MHS, and Brittany Williams, PhD,discuss key considerations to pre-exposure prophylaxis (PrEP) uptake in cisgender women, including:
The misconception by patients and healthcare professionals (HCP) that cisgender women are at low risk for HIV
Reframing HIV prevention from “risks” to “reasons” such as promoting self-care and taking control of one’s own sexual health
CDC PrEP guidance recommendations
Increasing PrEP awareness by sharing PrEP experiences with others in the community
The importance of community representation in PrEP marketing and campaigns
Challenges with finding HCPs who prescribe PrEP for cisgender women
Promoting self-advocacy when seeking care, including HIV prevention
Strategies for patients to engage with their HCPs to learn about and obtain PrEP
Available resources for PrEP coverage
Faculty:
Oni Blackstock, MD, MHS Founder & Executive Director
Health Justice
New York, New York
Brittany Williams, PhD Assistant Professor of Higher Education and Student Affairs Administration
Department of Education
University of Vermont
Burlington, Vermont
Link to full program: https://bit.ly/3PZGYdR
12 Jun 2020
COVID-19: Answering the Questions, Part 2
00:43:57
In this episode, Part 2 of an ongoing 12-part COVID-19 series, Jens D. Lundgren, MD, DMSc, provides a brief update on the latest incidence trends, a concise guide to viral diagnostic testing, and new data on investigational treatment options. After the update, Dr. Lundgren answers critical clinician questions on COVID-19 transmission, diagnosis, and management.
Presenter: Jens D. Lundgren, MD, DMSc Professor Director, Centre of Excellence for Health, Immunity and Infection (CHIP) Rigshospital University of Copenhagen Copenhagen, Denmark
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Questions Answered on ART Safety and Tolerability in Aging Patients and Populations With Cardiometabolic Toxicities
00:23:00
In this episode, Marta Boffito, MD, PhD, FRCP, and Jens D. Lundgren, MD, DMSc, address key considerations when evaluating antiretroviral therapy safety and tolerability in aging patients and those with possible cardiometabolic toxicities, including:
Approaching antiretroviral-related weight gain in clinical practice
Interpreting results from RESPOND on cardiovascular risk with integrase strand transfer inhibitors
Collaborating with other specialties (eg, cardiologists, dietitians) to provide a multidisciplinary approach for managing comorbidities, including prevention and management
Faculty:
Marta Boffito, MD, PhD, FRCP Consultant Physician/Professor HIV/Research Chelsea and Westminster Hospital Imperial College London London, United Kingdom
Jens D. Lundgren, MD, DMSc Professor Rigshospital, University of Copenhagen Director Centre of Excellence for Health, Immunity and Infection (CHIP) Rigshospital, University of Copenhagen Copenhagen, Denmark
Starting ART: Dialogues on Optimizing Engagement in HIV Care
00:42:27
In this podcast episode, Isolde Butler, MD, MPH, a healthcare professional caring for people living with HIV, and Marissa Gonzalez, an individual living with HIV, discuss strategies to improve healthcare professionals’ competencies in delivering optimal HIV care from the start to better support patients in overcoming barriers to sustained care engagement.
The topics they discuss include:
An introduction to the guidelines on ART initiation—start quickly and choose the therapy that is effective and tolerable
The patient experience, from initial diagnosis to treatment selection, noting that where people get diagnosed matters in determining the level of support they will receive
The complete HIV care team: healthcare professionals, navigators, case managers, behavioral health providers, mental health providers, and so on. Smaller clinics may not be able to provide adequate support to meet all patient needs
How to navigate the first visit after an HIV diagnosis, including patient–provider treatment discussions on the available therapies that can help with stigma
HIV stigma education; navigating the miseducation and misinformation
Presenters:
Isolde F. Butler, MD, MPH Chief Medical Officer Cresentcare New Orleans, Louisiana
Marissa Gonzalez Chair Community Advisory Board The Well Project
Starting HBV Treatment in Pregnancy: Conversations Between Patient and Physician #3
00:11:02
Episode 3 of this series features Anna Cristina L. dela Cruz, MD, in conversation with patient Melody Cheng about Melody’s decision to start hepatitis B virus (HBV) antiviral therapy during pregnancy. This podcast also discusses recommended approaches to preventing HBV transmission from mother to child, current recommendations on starting treatment for chronic HBV infection, and the issues around stopping treatment.
Presenter: Anna Christina L. dela Cruz, MD Associate Professor Division of Digestive Diseases and Nutrition Department of Internal Medicine University of Kentucky Lexington, Kentucky
Content based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.
Key Decisions in HIV Care: Switching to a 2-Drug Single-Tablet Regimen
00:18:11
In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on switching to 2-drug single-tablet ART regimens.
Listen as he gives his perspectives on:
Indications for the available 2-drug single-tablet regimens: DTG/RPV and DTG/3TC
The SWORD-1 and SWORD-2 studies evaluating switching to DTG/RPV in virologically suppressed patients
Real-world experience with switching to DTG/RPV from the OPERA study
The TANGO study evaluating switching to DTG/3TC from a stable TAF-based ART regimen
The SALSA study evaluating switching to DTG/3TC from any stable 3-drug ART regimen
Presenter: William R. Short, MD, MPH, AAHIVS Associate Professor of Medicine Division of Infectious Diseases Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania
In this first of 3 episodes, global HIV experts and advocates discuss how innovative models of care are minimizing barriers to HIV care engagement to improve uptake by key underserved populations, including:
How peer support programs empower people to combat stigma, become more educated about treatment, and be engaged participants in their HIV care
Strategies for addressing potential unmet mental healthcare needs among people living with HIV
Approaches to reengage people with HIV who transit through county jail systems
How integrated care strategies and wrap-around services can overcome some of the barriers to care that are associated with social determinants of health
Key considerations when providing HIV care for migrant and refugee populations
Faculty:
Ann Avery, MD Professor of Medicine Case Western Reserve University Division of Infectious Diseases MetroHealth Medical Center Cleveland, Ohio
Jennifer Blanchette, PhD Independent Contractor Clinical Care Options Colorado, United States
Isolde Butler, MD, MPH Chief Medical Officer CrescentCare New Orleans, Louisiana
Monica Gandhi, MD, MPH Professor of Medicine Division of HIV, Infectious Diseases, and Global Medicine Director, Center for AIDS Research (CFAR) Medical Director, Ward 86 HIV Clinic University of California, San Francisco (UCSF) San Francisco, California
Marissa Gonzalez Chair Community Advisory Board The Well Project
Angelina Namiba Founder Member 4M Network of Mentor Mothers London, United Kingdom
Chloe Orkin, MBChB, FRCP, MD Professor of Infection and Inequities Faculty of Medicine and Dentistry Queen Mary University of London Blizard Institute Barts Health NHS Trust London, United Kingdom
Miłosz Parczewski, MD, PhD Professor of Medicine Department Head Consultant in Infectious Diseases Department of Infectious, Tropical Diseases and Acquired Immunodeficiency Pomeranian Medical University Szczecin, Poland
In this episode, Gregory Huhn, MD, presents a case study exploring how to optimize oral ART for a person with a long history of different ART regimens.
Listen as he discusses:
Reasons to consider regimen optimization in the setting of viral suppression
Evidence for INSTIs in the setting of resistance
Data on when 2-drug regimens and long-acting regimens may or may not be good options
Faculty
Gregory Huhn, MD Interim Chief, Division of Infectious Diseases Senior Director of HIV Services Cook County HIV Integrated Programs Interim Medical Director, The RMR CORE Center Professor, Division of Infectious Diseases Rush University Medical Center Chicago, IL
Get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify.
13 Jan 2023
Emerging Insights on Outpatient Management of Acute COVID-19 and Long COVID in Europe
00:40:04
In this episode, Jens D. Lundgren, MD, DMSc, and Barbara Rath, MD, PhD, HDR, discuss emerging insights on outpatient management of acute COVID-19 and long COVID in Europe, including:
Current COVID-19 variant and subvariant landscape
COVID-19 treatments, including antivirals and monoclonal antibodies
ESCMID COVID-19 treatment guidelines
Long COVID causes and pathophysiology
Prevention and management of long COVID
Presenters:
Jens D. Lundgren, MD, DMSc Professor Rigshospital, University of Copenhagen Director Centre of Excellence for Health, Immunity and Infection (CHIP) Rigshospital, University of Copenhagen Copenhagen, Denmark
Barbara Rath, MD, PhD, HDR Co-founder and Chair Vaccine Safety Initiative, Berlin, Germany/USA Research Director Université de Bourgogne-Franche-Comté, France Executive Board Member ESGREV (Respiratory Virus Study Group for ESCMID) ISIRV Chair ISIRV-Epidemiology Group
2023 Audio Recap: Practical Case Studies in Outpatient COVID-19 Management
00:57:16
In this episode, Tracey Piparo, PA-C, and Renslow Sherer, MD, discuss cases of nonhospitalized patients with COVID-19, including:
Young, healthy patient with no risk factors
Young, healthy patient with risk factors
Older patient with immunocompromise
Older patient with renal dysfunction
Patient experiencing hypoxia
Presenters:
Tracey Piparo, PA-C Department of Palliative Medicine RJWBarnabas New Brunswick, New Jersey
Renslow Sherer, MD Director, International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois
An HIV Vaccine: An Unfulfilled Promise—Episode 2, Learning Through Failing
00:27:30
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Susan Buchbinder and Mr. Jontraye Davis discuss what has been learned and built through the past 40 years of HIV vaccine research, including how HIV vaccine scientific advancements and infrastructure were critical to the success of developing a COVID-19 vaccine.
Presenters:
Susan Buchbinder, MD Clinical Professor Departments of Medicine, Epidemiology and Biostatistics University of California, San Francisco Director, Bridge HIV San Francisco Department of Public Health San Francisco, California
Jontraye Davis, MHA, PMD Pro Community Program Manager FHI 360 Adjunct Instructor North Carolina Central University Durham, North Carolina
Special Commentator:
Jerome H. Kim, MD Director General International Vaccine Institute Seoul, South Korea
Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
29 Oct 2024
Be an HPV Vaccine Champion: Reaching Underserved Populations
00:26:10
Listen in as Rebekah Fenton, MD, MPH, and Sharon G. Humiston, MD, MPH, discuss strategies to achieve health equity in HPV vaccination, including:
Trends among males vs females
Messaging considerations for those from diverse populations (eg, LGTBQ+ and rural communities)
How healthcare professionals can address barriers to care
Then, hear answers from the experts to frequently asked questions regarding HPV vaccination recommendations, timing, and example case studies.
Presenters: Rebekah Fenton, MD, MPH Adolescent Medicine Physician Alivio Medical Center Chicago, Illinois
Sharon G. Humiston, MD, MPH Director for Research Associate Editor of IZ-Express Immunize.org Rochester, New York
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Key COVID-19 Studies Influencing My Practice Following IDWeek 2022—Audio Recap
00:37:17
In this episode, Princy N. Kumar, MD, and Paul E. Sax, MD, discuss new COVID-19 data from IDWeek 2022, including:
COVID-19 vaccines, including omicron BA.1 bivalent booster
Risk factors for breakthrough COVID-19 infections
COVID-19 diagnostics, including digital droplet PCR
COVID-19 therapeutics, including:
Nirmatrelvir plus ritonavir
Tixagevimab plus cilgavimab
Baricitinib
Tocilizumab
Inhaled interferon β-1a
COVID-19 therapeutics and outcomes in patients with immunocompromise
Long COVID
Presenters: Princy N. Kumar, MD, FIDSA, MACP Professor of Medicine and Microbiology Chief, Division of Infectious Diseases and Travel Medicine Senior Associate Dean of Students Georgetown University School of Medicine Washington, DC
Paul E. Sax, MD Clinical Director HIV Program and Division of Infectious Diseases Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts
First Cohort With HIV: Paving the Path for the Future
00:11:20
In this episode, hear HIV activist Marc Thompson share his perspectives on aging with HIV including:
His early experiences after receiving his diagnosis
Persisting issues of the HIV epidemic including stigma and discrimination
Changes in healthcare with the advent of HIV treatment
Added issues of aging with HIV like polypharmacy, multimorbidity, and mental health concerns (eg, loneliness, social isolation)
Actions needed to improve the path for the future: addressing opportunities to expand research, improve collaboration between HIV and other healthcare professionals and gain wisdom and knowledge from others aging with HIV
You can also join Marc Thompson and a panel of patient advocates and healthcare professionals in person or in a live simulcast as they discuss healthy aging with HIV at our live symposium at AIDS 2022 in Montreal, Quebec, Canada. They will discuss the challenges faced by older people with HIV, including medical and nonmedical issues, and specific challenges faced by subgroups of older patients such as women and patients in resource-limited settings.
23 Jun 2023
Older Adults: Overcoming HBV Barriers
00:39:55
In this episode, Robert S. Brown, Jr., MD, MPH; Nancy Reau, MD; and Eric, a person living with chronic hepatitis B, discuss solutions for overcoming barriers to HBV care in older adults, including:
Awareness of HBV and CHB in older adults
Updated HBV screening and vaccination recommendations
Monitoring of renal and bone disease
Adjustment of monitoring and treatment as a person with HBV ages
Presenters: Robert S. Brown, Jr., MD, MPH Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Weill Cornell Medicine New York, New York
Nancy Reau, MD Professor of Medicine Chief, Section of Hepatology Associate Director, Solid Organ Transplantation Richard B. Capps Chair of Hepatology Rush University Medical Center Chicago, Illinois
Eric, person living with chronic hepatitis B
Link to downloadable slides: please link to VM404 downloadable slides when ready
Key Viral Hepatitis Studies Influencing My Practice Following AASLD 2021
00:38:53
In this episode, Nancy Reau, MD, discusses new viral hepatitis data from AASLD 2021, including:
HBV treatment in pregnancy
Outcomes following HBV treatment withdrawal
Progress toward an HBV cure
HCV implementation science and current status of the cascade of care
Hepatitis delta virus: understanding the clinical impact
Phase III clinical trial updates for hepatitis delta virus, including data on bulevirtide
Presenter:
Nancy Reau, MD Professor of Medicine Chief, Section of Hepatology Associate Director, Solid Organ Transplantation Richard B. Capps Chair of Hepatology Rush University Medical Center Chicago, Illinois
4th HIV Research for Prevention Conference (HIVR4P // Virtual)—Rapid Recap
00:38:18
In this episode, Dr. Bekker discusses results from key studies reported at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), including results from studies evaluating novel approaches to HIV prevention such as broadly neutralizing antibodies, long-acting injectable and oral ARVs, and implantable options. In addition, Dr. Bekker will discuss several studies evaluating different aspects of PrEP implementation and acceptance as well as considerations for multipurpose prevention strategies.
Presenter:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Director Desmond Tutu HIV Centre Past President International AIDS Society Faculty of Health Sciences University of Cape Town Cape Town, South Africa
Content based on a CME program supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Managing HIV in Aging Patients: Answering the Questions, Part 1
00:38:50
In this episode, Part 1 of an 4-part series, Dr. Joseph J. Eron, Jr., Professor Chloe Orkin, and Dr. Paul E. Sax, discuss key health challenges faced by aging patients with HIV and answer clinicians’ questions on HIV treatment considerations and on prevention, screening, and treatment of common age-related comorbidities.
Presenters: Joseph J. Eron, Jr., MD Professor of Medicine and Epidemiology University of North Carolina School of Medicine Director, AIDS Clinical Trials Unit University of North Carolina Chapel Hill, North Carolina
Chloe Orkin, MBChB, FRCP, MD Professor of HIV Queen Mary, University of London Consultant Physician Lead for HIV Research Barts Health NHS Trust The Royal London Hospital London, United Kingdom
Paul E. Sax, MD Clinical Director HIV Program and Division of Infectious Diseases Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts
Content based on an online CME/CE/CPE-certified program supported by educational grants from Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and ViiV Healthcare.
Strategies to Improve HPV Vaccine Uptake: Effective Vaccine Messaging
00:13:35
Listen in as Rebekah Fenton, MD, MPH, and Sharon G. Humiston, MD, MPH, discuss strategies to improve your messaging techniques with the HPV vaccine, including:
Persisting in vaccine recommendation after initial refusal
Educating patients and their families together
Ensuring staff are trained to correctly answer questions
Knowing when interested patients in your state can consent to vaccination without needing parental consent
Presenters: Rebekah Fenton, MD, MPH Adolescent Medicine Physician Alivio Medical Center Chicago, Illinois
Sharon G. Humiston, MD, MPH Director for Research Associate Editor of IZ-Express Immunize.org Rochester, New York
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Yvonne Gilleece, MB BCh, BAO, FRCP, uses a case study to illustrate why giving people space and time to engage in HIV care on their terms is key to overcoming potential shame and stigma.
She discusses how people can be very vulnerable when engaging in HIV care, and trauma-informed care can help address these vulnerabilities in a safe, respectful way. Listen as she gives her perspectives on:
Trauma-informed care
Overcoming stigma and shame
Staying in care
Presenter: Yvonne Gilleece, MB BCh, BAO, FRCP Honorary Clinical Professor and Consultant in HIV Medicine & Sexual Health Brighton & Sussex Medical School and University Hospitals Sussex NHS Foundation Trust Chair of the British HIV Association Lead for HIV & Women Lead for HIV & Hepatitis Brighton, United Kingdom
Content based on an online CME program supported by an educational grant from Gilead Sciences, Inc.
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
05 Feb 2025
Defining Best Practices in HBV Care
00:34:14
In this episode, Patricia D. Jones, MD, MSCR; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD; and patient advocate, Jennifer Wild, MS, RN, OCN, discuss best practices in hepatitis B virus (HBV) care, including:
2023 CDC HBV screening recommendations
Summary of guideline recommendations for hepatitis delta virus (HDV) screening
Use of HDV reflex testing to avoid loss to follow-up
2024 WHO HBV treatment recommendations, including recommendations for pregnant persons
Presenters:
Patricia D. Jones, MD, MSCR Associate Professor of Clinical Medicine Director of Clinical Operations-Hepatology Division of Digestive Health and Liver Diseases Department of Medicine University of Miami Miller School of Medicine Sylvester Comprehensive Cancer Center Miami, Florida
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Professor of Medicine (GI & Hepatology, Liver Transplant) Professor of Epidemiology & Population Health (by Courtesy) Director of Hepatology Clerkship Faculty Search LENS Advocates, Stanford Department of Medicine Faculty Fellow, Stanford Center for Innovation in Global Health Member, Stanford Cancer Institute, Maternal & Child Health Research Institute, & Stanford Bio-C Stanford, California
Past Chair: HBV SIG, The American Association for the Study of Liver Diseases (AASLD)
28th President: The International Association for the Study of the Liver (IASL)
Jennifer Wild, MS, RN, OCN Clinical Nurse – GI Medical Oncology UCSF Cancer Center San Francsico, California
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
13 Nov 2023
PrEP Today: An HIV Prevention Revolution
00:26:25
In this episode, global PrEP experts and advocates discuss how current PrEP regimens represent a revolutionary step forward in enabling many individuals to avoid HIV acquisition, including:
How PrEP has empowered people to take control of their sexual lives, revolutionized people’s sexual experiences, and, for some, improved their experiences with healthcare in general
The extraordinary progress that has been made in New South Wales and specifically in inner Sydney toward HIV transmission elimination and the role of PrEP in the prevention of new HIV infections
The importance of having PrEP options, including on-demand options and long-acting formulations, available to different populations who could benefit to see progress toward HIV transmission elimination globally
Faculty:
Jessica L. Adams, PharmD, AAHIVE Scientific Director, Infectious Diseases Clinical Care Options New York, United States
Linda-Gail Bekker, MBChB, DCH, DTM&H, FCP(SA), PhD Professor and Director The Desmond Tutu HIV Centre University of Cape Town South Africa Chief Executive Officer The Desmond Tutu Health Foundation Cape Town, South Africa
Kenyon R. Farrow PrEP Advocate Vice President of Policy Point Source Youth Contributing Editor TheBody.com Ohio, United States
Beatriz Grinsztejn, MD, PhD Director STI/AIDS Clinical Research Laboratory Instituto Nacional de Infectologia Evandro Chagas-Fiocruz Rio de Janeiro, Brazil
Andrew Grulich, MBBS, PhD Scientia Professor Head, HIV Epidemiology and Prevention Program The Kirby Institute University of New South Wales, Sydney New South Wales, Australia
Jean-Michel Molina, MD, PhD Professor of Infectious Diseases University of Paris Cité Head of the Department of Infectious Diseases Hospital Saint-Louis and Lariboisière Paris, France
Brittany Williams, PhD PrEP Advocate Assistant Professor of Higher Education and Student Affairs Administration Department of Education University of Vermont Vermont, United States
Contemporary Management of HIV: Selecting Among Current ART Regimens for Initial ART
00:25:24
In this episode, W. David Hardy, MD, discusses current guidelines and clinical trial data informing optimal selection of first-line antiretroviral therapy for HIV.
Presenter:
W. David Hardy, MD Scientific and Medical Consultant Adjunct Professor of Medicine Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore, Maryland
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Cutting-Edge Concepts in HIV Care: Long-Acting Therapies
00:19:31
In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including:
Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)
Risk factors for virologic failure of LA CAB + RPV
The ATLAS-2M study
Combined clinical trials of LA CAB + RPV
Practical considerations for LA CAB + RPV
Implementation of LA CAB + RPV
Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension study
Supporting candidates for LA antiretroviral therapy (ART)
Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San Francisco
Future LA ART
The investigational LA HIV capsid inhibitor lenacapavir (LEN)
LEN resistance from the CAPELLA and CALIBRATE studies
LEN injection-site reactions in the CAPELLA and CALIBRATE studies
Presenter:
Paul E. Sax, MD Clinical Director HIV Program and Division of Infectious Diseases Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts
Actively Countering Health Disparities to Improve PrEP Uptake
00:15:09
In this episode, Roger Bedimo, MD, MS, FACP, discusses strategies to overcome health disparities to improve PrEP uptake, including:
Targeting key populations that would benefit from PrEP but have low rates of uptake, such as transgender women and people who inject drugs
Addressing intersectionality
Overcoming implicit bias
Addressing PrEP inequity by geographic region
Expanding PrEP uptake by expanding HCPs who prescribe it
Improving PrEP education for both patients and HCPs
Presenter: Roger Bedimo, MD, MS, FACP Professor of Medicine Interim Director, Office of Global Health UT Southwestern Medical Center Chief, Infectious Diseases Section VA North Texas Health Care System Dallas, Texas
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
18 Jan 2023
How Clinic Facilities Can Prepare for Long-Acting Injectable Antiretroviral Therapy
00:05:07
In this episode, Eric Florence, MD, PhD, discusses how clinics can prepare for the implementation of long-acting injectable antiretroviral therapy, including:
Clinical infrastructure
Ensuring adequate space and injection equipment
Maintaining drug supply and temperature requirements
Staffing
Ensuring there are staff able to focus on the implementation of LA ART, including well-trained nurses to administer the injections
Implementing a system for scheduling follow-up injections and providing patient reminders
Having knowledgeable staff available to answer patient questions on their LA ART
Eric Florence, MD, PhD Physician Internal Medicine, Infectious Diseases & Tropical Medicine University Hospital of Antwerp Edegem, Brussels, Belgium
Lessons From Lockdown: Caring for Patients With Hepatitis B Virus Infection in the COVID-19 Era—Audio Recap
00:26:09
In this episode, Drs Norah Terrault, MD, MPH, and Grace LH Wong, MD, share lessons learned in the care of patients with hepatitis B virus (HBV) in the COVID-19 era, including:
HBV cascade of care before vs during the pandemic
Innovative strategies to improve HBV diagnosis and linkage to care
Lessons learned in telemedicine
Elimination through vaccination
Management of HBV and COVID-19 coinfection
Management of elevated liver enzymes in COVID-19
Presenters:
Norah Terrault, MD, MPH Professor of Medicine Chief ofGastrointestinal and Liver Diseases University of Southern California Los Angeles, California
Grace LH Wong, MD Professor Director, Medical Data Analytics Centre (MDAC) Deputy Director, Center for Liver Health Assistant Dean (Learning Experience), Faculty of Medicine The Chinese University of Hong Kong Honorary Consultant Division of Gastroenterology and Hepatology Department of Medicine and Therapeutics Prince of Wales Hospital Hong Kong
Emerging Insights on Adverse Events During ART and Implications for Treatment
00:41:04
In this episode, Joseph J. Eron, Jr., MD, and Darcy Wooten, MD, share insights on HIV antiretroviral therapy safety and tolerability including recent data on weight gain and metabolic implications with INSTIs and NRTIs as well as the latest updates and recommendations on dolutegravir and pregnancy.
Joseph J. Eron, Jr., MD Professor of Medicine and Epidemiology University of North Carolina School of Medicine Director, AIDS Clinical Trials Unit University of North Carolina Chapel Hill, North Carolina
Darcy Wooten, MD Associate Professor of Medicine Division of Infectious Diseases and Global Public Health Department of Medicine University of California, San Diego San Diego, California
Content based on a CME program supported by independent educational grants from Janssen Therapeutics, Division of Janssen Products, LP, and ViiV Healthcare
Conference Conversations: HIV Pharmacist Perspectives from CROI 2022
00:19:18
In this episode, Fidelia Bernice, PharmD, and Jennifer Cocohoba, PharmD, share insights on new HIV data from CROI 2022, including:
Islatravir tissue and plasma distribution after monthly oral dosing
Pharmacokinetics, safety, and acceptability of a tenofovir vaginal ring
PrEP and Hormone Therapy in Transgender Individuals
Anticholinergic drug effects in older PWH
Adherence in PWH
Presenters:
Fidelia Bernice, PharmD Clinical Pharmacy Specialist, Infectious Diseases Department of Pharmacy University of Maryland Medical Center Baltimore, Maryland
Jennifer Cocohoba, PharmD Professor Department of Clinical Pharmacy University of California, San Francisco San Francisco, California
In this episode, Helen Y. Chu, MD, MPH, shares updates on RSV seasonality, including:
Surveillance limitations due to the testing availability in adults
Current 2023/2024 season trends, including predictions for other respiratory viruses (eg, influenza, SARS-CoV-2)
Considerations for RSV administration
RSV vaccine coadministration with influenza and COVID-19 vaccines
Faculty:
Helen Y. Chu, MD, MPH Associate Professor of Medicine Division of Allergy & Infectious Diseases University of Washington School of Medicine Seattle, Washington
ART Safety Considerations in Aging Patients With HIV
00:18:53
In this episode, hear Marta Boffito, MD, PhD, FRCP, and Julian Falutz, MD, FRCPC, discuss their approach to minimizing antiretroviral (ARV)-related intolerances in older patients with HIV, including:
Consequences of polypharmacy
Deprescribing ARV and non-ARV medications
Complications associated with aging (eg, geriatric syndromes such as falls, frailty, multimorbidity)
Mediations to avoid, such as anticholinergic medications, to minimize drug–drug interactions and risk of developing geriatric syndromes
Faculty:
Marta Boffito, MD, PhD, FRCP Consultant Physician/Professor HIV/Research Chelsea and Westminster Hospital Imperial College London London, United Kingdom
Julian Falutz, MD, FRCPC Associate Professor of Medicine Department of Medicine McGill University School of Medicine Director Comprehensive HIV and Aging Initiative Chronic Viral Illness Service McGill Montreal, Quebec, Canada
Overcoming HBV Barriers: Focus on Asian American People
00:52:07
In this episode, Joseph Lim, MD; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD; and Jennifer Wild, MS, BSN, RN, OCN, discuss strategies for overcoming barriers to HBV care in Asian American people, including:
HBV-related stigma
Language barriers
Health insurance navigation
Presenters:
Joseph Lim, MD Professor of Medicine Director, Clinical Hepatology Vice-Chief, Section of Digestive Diseases Yale University School of Medicine New Haven, Connecticut
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Professor of Medicine (GI & Hepatology, Liver Transplant) Professor of Epidemiology & Population Health (By Courtesy) Director of Hepatology Fellowship Director of Hepatology Clerkship Stanford University Medical Center Palo Alto, California
Jennifer Wild, MS, BSN, RN, OCN Clinical Nurse UCSF Helen Diller Family Comprehensive Cancer Center GI Medical Oncology, Outpatient Hepatobiliary Program Oakland, California
Link to downloadable slides: please link to VM401 downloadable slides when ready
Link to program: please link to HEP 2023 HBV Key Communities VM (PRP5676) when ready
20 Oct 2022
Switching ART in a Virologically Suppressed Person With Suspected Underlying Resistance
00:07:08
In this episode, Timothy J. Wilkin, MD, MPH, provides a case-based overview of switching antiretroviral therapy in a patient with viral suppression on their current regimen who has a history of virologic failure with drug-resistance mutations. Key findings from 2 relevant studies—the SWITCHMRK trial and Study 380-4030—are reviewed. The case discussion also highlights several other challenges that can be encountered in the switch setting, including incomplete immune recovery, comorbidities, and gastrointestinal intolerability of some antiretroviral drugs.
Presenter:
Timothy J. Wilkin, MD, MPH Professor Medicine Division of Infectious Diseases Weill Medical College of Cornell University New York, New York
Content based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare.
Key Decisions in HIV Care: Considering the Use of Proviral DNA Genotyping to Inform ART Choice
00:17:56
In this episode, John D. Baxter, MD, explores recommendations and data on the use of proviral DNA genotyping to inform antiretroviral therapy (ART) choice for patients who are treatment experienced.
Listen as he gives his perspectives on:
US Department of Health and Human Services guideline recommendations on the use of proviral DNA genotyping
US Department of Health and Human Services guideline recommendations and supporting data on switching ART with viral suppression and underlying drug resistance
Study 380-4030 on outcomes with bictegravir- and dolutegravir-based ART in patients with preexisting nucleos(t)ide reverse-transcriptase inhibitor resistance
The BRAAVE 2020 study on switching to bictegravir/emtricitabine/tenofovir alafenamide in Black persons with HIV, some of whom had baseline ART resistance
Between-class ART switches with underlying resistance
Susceptibility of tenofovir disoproxil fumarate and abacavir with thymidine analogue mutations
Presenter:
John D. Baxter, MD Professor of Medicine Division of Infectious Diseases Department of Pathology Cooper Medical School of Rowan University Head, Division of Infectious Diseases Cooper University Health Care Camden, New Jersey
In this episode, Roger Bedimo, MD, MS, FACP, examines provider-based and structural PrEP barriers and discusses practical methods for healthcare professionals to overcome these challenges. Topics covered include:
Potential provider barriers to prescribing PrEP
Strategies to facilitate conversations about PrEP
Addressing the gap in PrEP provider training
Structural barriers for PrEP coverage, such as lack of insurance and complexity of billing
Informed consent for minors
CDC guidelines on HIV testing and renal or lipid monitoring while on PrEP
The role of PrEP champions or PrEP navigators, such as in the SNAPS PrEP Navigation Program
Solutions to common problems with PrEP persistence, such as use of telehealth and same-day PrEP initiation
Expanding PrEP options
Presenter:
Roger Bedimo, MD, MS, FACP Professor of Medicine Interim Director, Office of Global Health UT Southwestern Medical Center Chief, Infectious Diseases Section VA North Texas Health Care System Dallas, Texas
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
CRE-ating Success: How I Use Rapid Diagnostic Tests to Manage Carbapenem-Resistant Enterobacterales Bacteremia
00:15:53
In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:
Burden of CRE infections in the United States
Mechanisms of resistance
Changing epidemiology
Use of rapid diagnostic tests
IDSA guidance recommendations, including supporting data
Approach to designing treatment regimens, including weighing patient- and infection-related factors
Faculty:
Julie Ann Justo, PharmD, MS, FIDSA, BCPS Clinical Pharmacist Lead – Infectious Diseases Inpatient Pharmacy Dartmouth Hitchcock Medical Center Lebanon, New Hampshire
Respiratory Syncytial Virus in Older Adults: Understanding Risk, Diagnosis, and Evolving Prevention Strategies
00:51:35
In this podcast, Spencer H. Durham, PharmD, BCPS, BCIDP; Stefan Gravenstein, MD, MPH; and Barbara Resnick, PhD, CRNP, discuss risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccines for older adults. Following their dialogue, the faculty field questions from healthcare professionals.
Presenters:
Spencer H. Durham, PharmD, BCPS, BCIDP Associate Clinical Professor of Pharmacy Practice Director, Alumni & Professional Affairs Clinical Affairs & Outreach Auburn University Harrison School of Pharmacy Auburn, Alabama
Stefan Gravenstein, MD, MPH Director Division of Geriatrics and Palliative Medicine The Warren Alpert Medical School of Brown University Providence, Rhode Island
Barbara Resnick, PhD, CRNP Professor School of Nursing University of Maryland Nurse Practitioner Roland Park Place Baltimore, Maryland
Content based on an online CME program supported by educational grants from Janssen Therapeutics, Division of Janssen Products, LP.
In this episode, Daniel R. Kuritzkes, MD, discusses considerations for rapid initiation of antiretroviral therapy in patients who are newly diagnosed with HIV, including:
Recommended regimens
Management of patients previously receiving PrEP
Timing of laboratory testing
Presenter:
Daniel R. Kuritzkes, MD Harriet Ryan Albee Professor of Medicine Harvard Medical School Chief, Division of Infectious Diseases Brigham and Women’s Hospital Boston, Massachusetts
Key HIV Studies From CROI 2024 Influencing Clinical Practice
00:44:22
In this episode, Joseph J. Eron, Jr., MD, and Monica Gandhi, MD, MPH, discuss the key HIV studies from CROI 2024 that are influencing their clinical practice, including:
New data surrounding long-acting ART, including:
The CARES study of LA CAB + RPV in a Sub-Saharan African population using a public health approach
The IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIV
The ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ART
Updated data from San Francisco’s Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baseline
Case series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV alone
Data on comorbidities and coinfections, including:
A REPRIEVE proteomic analysis to elucidate mechanistic pathways of statin effects on plaque
The ACTG A5371 SLIM LIVER study of semaglutide for MASLD in people living with HIV
The impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San Francisco
Potential novel treatment options on the horizon for people living with HIV, including:
Phase II data on LEN + ISL dosed orally once weekly
Early data on other oral weekly options
Data on bNAbs in combination or with other ART agents
Presenters:
Joseph J. Eron, Jr., MD Professor of Medicine, School of Medicine Herman and Louise Smith Distinguished Professor Chief, Division of Infectious Diseases Director, Clinical Core, UNC Center for AIDS Research Adjunct Professor of Epidemiology Gillings School of Global Public Health University of North Carolina at Chapel Hill Chapel Hill, North Carolina
Monica Gandhi, MD, MPH Professor of Medicine Division of HIV, Infectious Diseases, and Global Medicine Medical Director, Ward 86 HIV Clinic University of California, San Francisco San Francisco, California
Content based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.
27 Apr 2021
Cases and Controversies in HIV: ART Simplification
00:18:47
In this episode, Drs José R. Arribas, Andrew Carr, and Lynora Saxinger discuss simplification strategies for a virologically suppressed patient with HIV and a complex ART treatment history.
Presenters:
José R. Arribas, MD Research Director, HIV and Infectious Diseases Hospital La Paz IdiPAZ Madrid, Spain
Andrew Carr, MBBS, MD, FRACP, FRCPA Professor of Medicine University of New South Wales Director, HIV and Immunology Unit St Vincent’s Hospital Sydney, Australia
Lynora Saxinger, MD, FRCPC, CTropMed Cochair, Scientific Advisory Group Alberta COVID-19 Emergency Coordination Centre Associate Professor Division of Infectious Diseases Department of Medicine University of Alberta Edmonton, Alberta Canada
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
In this episode, Nancy Reau, MD, discusses new viral hepatitis data from EASL 2022, including:
Novel therapeutics for HBV
Therapeutic vaccination for HBV
Emerging treatment options for HDV
HCV care cascade
HCC monitoring after HCV cure
Presenter:
Nancy Reau, MD Professor of Medicine Chief, Section of Hepatology Associate Director, Solid Organ Transplantation Richard B. Capps Chair of Hepatology Rush University Medical Center Chicago, Illinois
Providing Options for PrEP Reengagement: Strategies to Support PrEP Persistence and Reengagement
00:16:11
In this episode, Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES, discusses data and recommendations for providing HIV prevention options as a strategy to support PrEP persistence and engagement, including:
Postexposure prophylaxis (PEP) recommendations and the data for PEP-in-Pocket
Offering PrEP to everyone who receives PEP
Currently recommended PrEP options and the safety and adverse event considerations with each option
Monitoring recommendations for the different PrEP options
The importance of proactively addressing PrEP safety concerns that could lead to PrEP discontinuation
Faculty
Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES Assistant Professor Pharmacotherapeutics and Clinical Research University of South Florida Taneja College of Medicine Tampa, Florida
Podcast on On-Demand PrEP: Strategies to Support PrEP Persistence and Reengagement
00:15:06
In this episode, Jean-Michel Molina, MD, PhD, discusses the data and recommendations for considering on-demand PrEP as a strategy to support PrEP persistence and engagement for men who have sex with men, including:
Nondaily PrEP options recommended for cisgender men
Data from the ANRS IPERGAY study evaluating on-demand FTC/TDF vs placebo in men who have sex with men
Real-world data on the effectiveness of on-demand PrEP
Considerations for on-demand FTC/TDF in people with renal dysfunction
Data on hypertension and statin initiation risk with FTC/TAF PrEP
Data on weight gain with the different PrEP options
Faculty
Jean-Michel Molina, MD, PhD Professor of Infectious Diseases University of Paris Cité Head of the Department of Infectious Diseases Hospital Saint-Louis and Lariboisière Paris, France
PrEP Talks: Uptake in Racial and Ethnic Minority Men Who Have Sex With Men and Transgender Individuals
00:20:42
In this episode, Kenyon R. Farrow and Raphael J. Landovitz, MD, MSc, discuss key considerations to PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including:
Rates of HIV diagnoses in Black and Brown communities
Issues stalling success in HIV prevention (eg, stigma, healthcare coverage, and administration and operational barriers)
Considerations for healthcare professionals when discussing PrEP with patients
Importance of representation (eg, racial and ethnic minority people, transgender people) at clinic offices
Promoting cultural humility to build strong patient-provider relationships
Faculty:
Kenyon R. Farrow Vice President of Policy Point Source Youth Contributing Editor TheBody.com Cleveland, Ohio
Raphael J. Landovitz, MD, MSc Professor of Medicine Division of Infectious Diseases David Geffen School of Medicine University of California, Los Angeles Director, UCLA Center for Clinical AIDS Co-Director, Center for HIV Identification, Prevention, and Treatment Services Los Angeles, California
Modifying ART in the Presence of Hyperlipidemia: Using HIV-ASSIST
00:11:58
In this episode, Maunank Shah, MD, PhD, discusses using HIV-ASSIST to optimize treatment for both HIV and hyperlipidemia. Listen as he covers:
Hyperlipidemia and cardiovascular disease risk among people living with HIV
Recommendations for lipid screening for people living with HIV
Using HIV-ASSIST to support ART treatment decisions for people living with HIV with comorbidities
How HIV-ASSIST prioritizes certain ART agents in the setting of hyperlipidemia, including:
Deciding between bictegravir, doravirine, dolutegravir, raltegravir, and rilpivirine vs boosted protease inhibitors, including darunavir
Deciding between tenofovir disoproxil fumarate and tenofovir alafenamide or abacavir
How HIV-ASSIST incorporates drug‒drug interaction data from the University of Liverpool HIV Drug Interactions Checker and the DHHS guidelines when considering the use of statin therapy with ART
How HIV-ASSIST further incorporates drug resistance data from the Stanford HIV Drug Resistance Database
Maunank Shah, MD, PhD Associate Professor Infectious Diseases Johns Hopkins University Baltimore, Maryland
Trailblazers: Pharmacist’s Role in Optimizing New RSV Vaccines for Older Adults
00:19:46
In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman provide practical strategies for implementing RSV vaccination into practice, including:
Predicting and overcoming barriers to RSV vaccination
Presenters:
Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP Clinical Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey Internal Medicine Pharmacist Robert Wood Johnson University Hospital New Brunswick, New Jersey
Christina M. Madison, PharmD, FCCP, AAHIVP Clinical Pharmacist Founder and CEO, The Public Health Pharmacist, PLLC Adjunct Associate Professor of Pharmacy Practice Roseman University of Health Sciences College of Pharmacy Henderson, Nevada
Other program activities:
Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role https://bit.ly/49GUv1g
[After selecting the “Continue to Post Test” button:]
To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.
31 Dec 2020
COVID-19: Answering the Questions, Part 14
00:39:01
In this episode, Part 14 of an ongoing series, Vikramjit Mukherjee, MD, provides a brief update on COVID-19 mortality trends, including the latest data on overall and in-hospital fatality rates. After the update, Dr. Mukherjee answers clinician questions on various aspects of COVID-19.
Presenter:
Vikramjit Mukherjee, MD Assistant Professor of Medicine Division of Pulmonary, Critical Care, and Sleep Medicine New York University School of Medicine Director, Medical Intensive Care Unit Bellevue Hospital New York, New York
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Safety Considerations for HIV Treatments During Pregnancy
00:14:39
In this episode, hear Dr. Jean Rene Anderson and Dr. William Short discuss special factors to consider when selecting HIV treatments during pregnancy, including:
Key elements involved in evaluating ARV medications during pregnancy (eg, efficacy, pharmacokinetic, and safety data)
Approach to optimizing ART regimens prior to and during pregnancy
Faculty:
Jean Rene Anderson, MD Professor Department of Gynecology and Obstetrics Johns Hopkins University Director, Johns Hopkins HIV Women's Health Program Johns Hopkins Medical Institutions Baltimore, Maryland
William R. Short, MD, MPH, AAHIVS Associate Professor of Medicine Division of Infectious Diseases Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania
In this episode, Daniel R. Kuritzkes, MD, and Cristina Mussini, MD, discuss managing ART failure, including:
The definitions of virologic blips, low-level viremia, and virologic failure on ART
The infrequency of failure with resistance on first-line INSTI-based ART and the instances where this has occurred with BIC- and DTG-based ART in clinical trials and in the real world
The potential reasons for ART failure, including patient/adherence-related factors, HIV-related factors, and regimen-related factors
The impact of adherence on viral suppression with BIC- and DTG-based ART
Drug-drug interactions as a reason for failure of first-line INSTI-based ART
What to do if someone is experiencing virologic failure requiring an ART change
The use of proviral DNA testing in patients with viral suppression or low-level viremia with ART treatment experience
The impact of high HIV-1 RNA on ART effectiveness
The impact of NRTI resistance, including the M184V and K65R mutations, on the effectiveness of BIC- and DTG-based ART
Strategies to encourage and measure patient adherence to ART
Presenters
Daniel R. Kuritzkes, MD Harriet Ryan Albee Professor of Medicine Harvard Medical School Chief, Division of Infectious Diseases Brigham and Women’s Hospital Boston, Massachusetts
Cristina Mussini, MD Professor Department of Infectious Diseases University of Modena and Reggio Emilia Modena, Italy
NASH in PWH: Key Strategies for Screening and Identification
00:05:36
In this episode, Jürgen K. Rockstroh, MD, discusses his recommended approach for diagnosing nonalcoholic steatohepatitis in patients with HIV, the value of noninvasive diagnostic tests such as serum biomarkers and elastography, and how timely nonalcoholic fatty liver disease assessment and metabolic risk factor determination can result in early interventions.
Presenter: Jürgen K. Rockstroh, MD Professor of Medicine University Hospital Bonn Department of Medicine I Bonn, Germany
Content based on an online CME program supported by an educational grant from Theratechnologies Inc.
Contemporary Management of HIV 2021: First-line ART and Weight Gain—Audio Recap
00:16:48
In this episode, David A. Wohl, MD, discusses current guidelines and clinical trial data informing optimal selection of first-line antiretroviral therapy for HIV.
David A. Wohl, MD Professor of Medicine School of Medicine Site Leader, AIDS Clinical Trials Unit-Chapel Hill University of North Carolina at Chapel Hill Director, North Carolina AIDS Training and Education Center Chapel Hill, North Carolina Co-Director, HIV Services North Carolina Department of Correction Raleigh, North Carolina
What Challenges and Opportunities Exist With Implementation of Available Long-Acting ART?
00:13:25
In this episode, Iskandar Azwa, MBChB, MRCP; Nikos Dedes; Beng Eu, MBBS; Bernadette Sharp; and Jeff Taylor discuss challenges and opportunities with long-acting ART implementation, including:
Personal experiences with receiving LA ART
Views on long-acting ART in the development pipeline
Perspectives on self-administration of LA ART
Presenters:
Iskandar Azwa, MBChB, MRCP Associate Professor Infectious Diseases Faculty of Medicine University of Malaya Kuala Lumpur, Malaysia
Nikos Dedes Positive Voice Athens, Greece
Beng Eu, MBBS Doctor Prahran Market Clinic Melbourne, Victoria, Australia
Bernadette Sharp Advocate
Jeff Taylor Executive Director HIV+Aging Research Project Palm Springs, California
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Link to downloadable slides: https://clinicaloptions.com/CE-CME/infectious-disease/slides-fourth-90-and-la-art/17553-25368
The IAS COVID-19 Conference: Prevention – Rapid Recap
00:39:02
In this episode, Dr. Jens Lundgren discusses results from key studies reported at the IAS COVID-19 Conference: Prevention, including new findings on potential SARS-CoV-2 suppressive therapies, strategies for vaccination and mass testing, and interventions to prevent transmission of COVID-19 while maintaining desired outcomes in HIV care.
Jens D. Lundgren, MD, DMSc Professor Rigshospitalet, University of Copenhagen Copenhagen, Denmark Director Centre of Excellence for Health, Immunity and Infection (CHIP) Rigshospitalet, University of Copenhagen Copenhagen, Denmark
Content based on a CME program supported by an independent educational grant from Gilead Sciences, Inc.
Integrating New Data on LA ART From CROI 2023: Pharmacist Perspectives
00:10:24
In this episode, Amanda Binkley, PharmD, BCIDP, AAHIVP, and Nimish Patel, PharmD, PhD, AAHIVP, discuss clinically relevant data on long-acting ART from CROI 2023, including:
LA CAB + RPV in San Francisco’s Ward 86 Safety Net Clinic Serving Publicly Insured PWH
SOLAR: Randomized Switch to LA CAB + RPV From BIC/FTC/TAF
Amanda Binkley, PharmD, BCIDP, AAHIVP Clinical Pharmacy Specialist Infectious Disease Department of Pharmacy Penn Presbyterian Medical Center Philadelphia, Pennsylvania
Nimish Patel, PharmD, PhD, AAHIVP Professor Department of Clinical Pharmacy Skaggs School of Pharmacy & Pharmaceutical Sciences University of California La Jolla, California
In this episode, Dr. Orkin discusses results from key studies reported at AIDS 2020: Virtual, with new data on the following hot topics: current ART in principal populations, including older patients and women who become pregnant; metabolic outcomes during ART; HIV and COVID-19; investigational ART strategies; and HIV prevention. The overview includes:
The ADVANCE trial comparing initial ART with DTG plus FTC/TAF, DTG plus FTC/TDF, or EFV/FTC/TDF
A pooled analysis of randomized trials evaluating a switch to BIC/FTC/TAF in patients 65 years of age or older with virologic suppression on their current ART
A Kaiser Permanente study of BMI changes over time following ART initiation
An analysis of the longitudinal prospective OPERA cohort that assessed weight change with switch from TDF to TAF
Metabolic changes with switch from 3- or 4-drug TAF-based ART to 2-drug DTG/3TC in the TANGO study
Updated findings from the Tsepamo birth surveillance study in Botswana evaluating the prevalence of neural tube defects by antiretroviral exposure during conception/pregnancy
A retrospective study of COVID-19 in people with HIV presenting at 5 New York City Emergency Departments from March 2 to April 15, 2020
An analysis of protocol-defined virologic failure in the P011 study comparing islatravir plus DOR vs DOR/3TC/TDF in treatment-naive adults
A study evaluating the lenacapavir pharmacokinetic profile
Results from the HPTN 083 trial investigating the efficacy and safety of long-acting injectable cabotegravir vs daily oral TDF/FTC for PrEP in MSM and TGW
Presenter: Chloe Orkin, MBChB, FRCP, MD Professor of HIV Queen Mary, University of London Consultant Physician Lead for HIV Research Barts Health NHS Trust The Royal London Hospital London, United Kingdom
Content based on a CME program supported by independent educational grants from Gilead Sciences, Merck Sharp & Dohme Corp., and ViiV Healthcare.
In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, and Meredith Clement, MD, discuss PrEP initiation, including:
The importance of taking a sexual history and getting to know your patient
Recommendations for who should be considered for PrEP
Practicalities of PrEP initiation including laboratory assessments, interview and physical exam, evaluating concomitant medications, counseling, and prescribing
Summary of PrEP eligibility by regimen
Review of the clinical trial and real-world data for each PrEP modality
The likelihood of cross-resistance between PrEP options and ART options if someone were to become infected with HIV while receiving PrEP
Time to effective concentrations of PrEP after initiation
Whether there are data for on-demand dosing of FTC/TAF
Recommendations for FTC/TDF on demand for heterosexual cisgender men
Individualizing PrEP for each person to increase the likelihood of adherence, persistence, and efficacy
Recommendations for the use of LA CAB for PrEP during pregnancy and in people of childbearing potential
STI and point-of-care testing for people receiving PrEP
The possibility of implantable PrEP in the future
Presenters:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Professor and Director The Desmond Tutu HIV Centre University of Cape Town Cape Town, South Africa
Meredith Clement, MD Assistant Professor Section of Infectious Diseases Louisiana State University Health Sciences Center University Medical Center New Orleans, Louisiana
Contemporary Management of HIV 2021: Initiating First-line ART—Audio Recap
00:21:41
In this episode, William R. Short, MD, MPH, AAHIVS, discusses current guidelines and clinical trial data informing optimal selection of first-line antiretroviral therapy for HIV.
William R. Short, MD, MPH, AAHIVS Associate Professor of Medicine Division of Infectious Diseases Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania
Content based on a CME program supported by an independent educational grant from ViiV Healthcare.
Should We Screen Patients With HIV for NAFLD/NASH?
00:07:24
In this episode, hepatologist Giada Sebastiani, MD, discusses why the presence of obesity, metabolic syndrome, persistent elevation of ALT, or exposure to dideoxynucleoside analogues can trigger an evaluation for NAFLD and NASH, particularly in our aging population of patients with HIV with topics including:
Metabolic factors
HIV-related factors
Which patients with HIV are at risk
Presenter:
Giada Sebastiani, MD Associate Professor of Medicine McGill University Health Centre Division of Gastroenterology and Hepatology and Division of Infectious Diseases Clinician Scientist Research Institute of McGill University Health Centre Montreal, Quebec, Canada
Content based on an online CME program supported by an educational grant from Theratechnologies Inc.
Guidelines-Based Treatment for NTM Lung Disease: Application in Complex Patients
00:27:08
In this episode, Charles L. Daley, MD, discusses guideline-based treatment recommendations for nontuberculous mycobacterial (NTM) lung disease, including treatment regimens for:
Mycobacterium avium complex
M. kansasii
M. xenopi
We will also hear from a patient who describes the use of airway clearance devices and a patient who describes his typical NTM treatment course.
Finally, we hear Dr. Daley discuss a patient case with his colleagues, Shannon Kasperbauer, MD, and Pamela J. McShane, MD.
Presenters:
Charles L. Daley, MD
Professor of Medicine Division of Mycobacterial and Respiratory Infections National Jewish Health Denver, Colorado
Shannon Kasperbauer, MD
Associate Professor of Medicine Division of Mycobacterial and Respiratory Infections National Jewish Health Denver, Colorado
Pamela J. McShane, MD
Professor of Medicine Division of Pulmonary and Critical Care Medicine The University of Texas Health Science Center at Tyler Tyler, Texas
2023 Audio Recap: Principles of Outpatient COVID-19 Management
01:14:42
In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:
Current COVID-19 landscape
Rapid antigen tests and PCR tests
Risk stratification of patients who have a positive SARS-CoV-2 test
Antiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)
Long COVID
Presenters: Renslow Sherer, MD Director, International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois
Trinh P. Vu, PharmD, BCIDP Clinical Pharmacy Specialist in Infectious Diseases Department of Pharmaceutical Services Emory University Hospital Midtown Atlanta, Georgia
Key HIV Studies Influencing My Practice Following IDWeek 2021 – Audio Recap
00:41:36
In this episode, Darcy Wooten, MD, discusses new HIV data from IDWeek 2021, including:
A rapid test-and-treat program to start DTG/3TC in patients newly diagnosed with HIV (STAT)
Efficacy when switching from 3-drug to 4-drug TAF-based regimens to DTG/3TC (TANGO)
Virologic outcomes with 2-drug vs 3-drug ART regimens (Trio Health HIV Network Study)
Metabolic complications in treatment-naive patients (Study 1489 and Study 1490)
Resistance analysis of an investigational agent, lenacapavir (CALIBRATE)
The Positive Perspectives Survey to evaluate the U=U Educational Campaign in North American patients
Presenter:
Darcy Wooten, MD Associate Professor of Medicine Division of Infectious Diseases and Global Public Health Department of Medicine University of California, San Diego San Diego, California
Hepatitis Delta in Focus: Episode 1 of Answering the Questions on Screening, Diagnosis, and Treatment
00:22:43
In this episode, Maria Buti, MD, and Richard H. Davis, PA-C, address key considerations when screening, diagnosing, and treating patients with hepatitis delta virus (HDV), such as:
Barriers to screening
HDV screening based on patient risk factors
Universal screening for all patients with positive hepatitis B surface antigen (HBsAg)
Reflex testing
Availability of commercial testing
Monitoring suggestions in HBsAg positive and HDV antibody positive patients with negative HDV RNA
Limitations to evaluating advanced fibrosis in patients with HDV
Data on novel HDV therapies (eg, bulevirtide and lonafarnib)
Extending HDV therapy (eg, peginterferon) based on treatment response
Complicated Clinical Infections: Clinical Impact of New Data From ECCMID 2023
00:30:05
In this episode, David van Duin, MD, PhD, FIDSA, FAST, discusses new data on complicated clinical infections presented at ECCMID 2023, including:
Gram-negative resistance
Pharmacokinetic and clinical outcomes in patients receiving meropenem/vaborbactam for KPC-producing carbapenem-resistant Enterobacterales infections
Comparative study of cefiderocol- vs colistin-containing regimens for CRAB VAP with concomitant bacteremia
Real-world use of imipenem/cilastatin/relebactam for the treatment of infections caused by multidrug-resistant organisms
Antimicrobial stewardship
Safety and efficacy of antibiotic de-escalation from an antipseudomonal β-lactam in patients with Enterobacterales BSIs in SIMPLIFY
The SOAB study comparing clinical outcomes of switching to oral antibiotics after IV lead-in therapy vs continuing IV therapy in patients with Enterobacterales BSIs
Data from REGARD-VAP on outcomes of shortened antibiotic treatment for VAP guided by clinical criteria
Investigational agents
Open-label study following ATTACK of patients with colistin-resistant CRAB infections receiving sulbactam/durlobactam
Summary of findings from EAGLE-2 and EAGLE-3 of gepotidacin for uncomplicated UTI treatment
Post hoc DOOR analysis of SURE-2 of sulopenem for the treatment of complicated UTIs
Faculty: David van Duin, MD, PhD, FIDSA, FAST Professor of Medicine Director, Immunocompromised Host Infecious Diseases Program Division of Infectious Diseases University of North Carolina Chapel Hill, North Carolina
Content based on an online CME/CE program supported by an independent educational grant from Shionogi Inc.
In this episode, Renslow Sherer, MD, discusses key data on COVID-19 vaccine efficacy, including:
Third doses
Booster doses
Mixing and matching booster doses
Presenter:
Renslow Sherer, MD Director, International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois
Importance of Treatment for HBV: Patient and Physician Sharing Session #6
00:10:40
In episode 6 of an ongoing series of sharing sessions between a physician and patient, Tarik Asselah, MD, PhD, and his patient, who is living with chronic hepatitis B (CHB), discuss:
Importance and goals of hepatitis B virus (HBV) treatment, with a call for broader access to treatment worldwide
Screening for HBV, especially given the frequency of asymptomatic disease
HBV vaccination as a preventive measure
Living a healthy life and maintaining hope while living with CHB
Presenter:
Tarik Asselah, MD, PhD Professor of Medicine Department of Hepatology Hôpital Beaujon Université de Paris Clichy, France
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Managing HIV in Aging Patients: Answering the Questions, Part 2
00:40:13
In this episode, Part 2 of an 4-part series, Dr. Jonathan Appelbaum, Dr. Howard Grossman, and Professor Jürgen Rockstroh discuss key health challenges faced by aging patients with HIV and answer clinicians’ questions on HIV treatment considerations and on prevention, screening, and treatment of common age-related comorbidities.
Presenters:
Jonathan Appelbaum MD, FACP, AAHIVS Laurie L. Dozier Jr, MD, Education Director Professor of Medicine Chair, Department of Clinical Sciences Florida State University College of Medicine Tallahassee, Florida
Howard Grossman, MD Clinical Affiliate Assistant Professor Department of Integrated Medical Science Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Florida Medical Director, West Palm Beach, Wilton Manors, and Key West Midway Specialty Care Wilton Manors, Florida
Jürgen Rockstroh, MD Professor of Medicine University of Bonn Bonn, Germany
Content based on an online CME/CE/CPE-certified program supported by educational grants from Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and ViiV Healthcare.
Evolving Care of Heavily Treatment–Experienced Patients With HIV: Answering the Questions
00:36:36
In this episode, Roger Bedimo, MD, MS, FACP; Princy N. Kumar, MD, FIDSA, MACP; and Brian Wood, MD, answer healthcare professionals’ most pressing questions on caring for heavily treatment–experienced patients with HIV.
Faculty:
Roger Bedimo, MD, MS, FACP Professor of Medicine Division of Infectious Diseases University of Texas Southwestern Medical Center Section Chief Division of Infectious Diseases Department of Internal Medicine VA North Texas Health Care System Dallas, Texas
Princy N. Kumar, MD, FIDSA, MACP Professor of Medicine and Microbiology Chief, Division of Infectious Diseases and Tropical Medicine Senior Associate Dean of Students Georgetown University School of Medicine Washington, DC
Brian Wood, MD Associate Professor of Medicine Division of Allergy and Infectious Diseases University of Washington Seattle, Washington
Content based on an online CME/CPE-certified program supported by educational grant from ViiV Healthcare.
Addressing Age-Related Comorbidities Among People With HIV
00:29:36
In this episode, Dr. Kuritzkes and Dr. Ramers provide a case-based discussion addressing several age-related comorbidities among people with HIV, including bone loss, renal impairment, cardiovascular disease, mental health disorders, and neurocognitive disorders. Their discussion includes analysis of key data from the following HIV studies:
DRIVE-AHEAD: Neuropsychiatric Events With First-line DOR/3TC/TDF vs EFV/FTC/TDF
TANGO: Renal and Bone Changes With Switch to DTG/3TC
SWORD-1/2: Renal and Bone Changes With Switch to DTG + RPV
Study 1961: Quantitative Proteinuria by Baseline Regimen With Switch to BIC/FTC/TAF in Women
Studies 1216 and 1160: Bone Changes With Switch to RPV/FTC/TAF
NA-ACCORD: Increased MI Risk Among PWH
D:A:D: Increased CVD Risk With Boosted PIs
Danish HIV Cohort Study: Impact of Smoking on MI Risk
D:A:D: Impact of Smoking on MI Risk
In addition, Dr. Kuritzkes and Dr. Ramers discuss relevant data and practical strategies for smoking cessation among people with HIV as well as risk factors, pathogenesis, and challenges in the clinical management of HIV-associated neurocognitive disorders.
Presenters:
Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women’s Hospital Harriet Ryan Albee Professor of Medicine Harvard Medical School Boston, Massachusetts
Christian B. Ramers, MD, MPH Associate Clinical Professor Division of Infectious Diseases Department of Medicine UC San Diego School of Medicine La Jolla, California Chief, Population Health Director, Graduate Medical Education Family Health Centers of San Diego San Diego, California
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
An HIV Vaccine: An Unfulfilled Promise—Episode 4, Looking Toward a Fulfilled Promise
00:31:08
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode,Drs Elizabeth Bukusi, Peter Godfrey-Faussett, and Nina Russell discuss promising advances in the field of HIV vaccine research and how we can prepare for optimal rollout of an eventual HIV vaccine.
Presenters:
Elizabeth Anne Bukusi,MBChB, M.Med (ObGyn), MPH, PhD , PGD (Research Ethics), MBE (Research Ethics), CIP Senior Principal Clinical Research Scientist Center for Microbiology Research KEMRI Research Professor Departments of Global Health and Obstetrics and Gynecology University of Washington, Nairobi, Kenya Seattle, Washington
Peter Godfrey-Faussett, MBBS, FRCP(UK) Science Advisor United Nations Joint Programme on HIV (UNAIDS) Professor of Infectious Diseases and International Health London School of Hygiene and Tropical Medicine London, United Kingdom
Nina Russell, MD Director for TB and HIV Prevention Bill & Melinda Gates Foundation Seattle, Washington
Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
04 Dec 2023
Are We Making Our Patients Fight for PrEP?
00:03:52
In this episode, Martin Rios discusses how pre-exposure prophylaxis (PrEP) persistence depends on healthcare professional knowledge, including:
Their own experiences with the various PrEP providers they have seen
The relief that has come with seeing PrEP providers who are supportive and knowledgeable about the different PrEP options
The challenges that have come with seeing PrEP providers who are unwilling to prescribe PrEP altogether or who will prescribe PrEP when asked but are not knowledgeable about the options
Faculty:
Martin Rios PrEP User and Advocate Philadelphia, Pennsylvania
Piecing the Puzzle Together: Addressing Medical Challenges in Older PWH
00:13:03
In this podcast, Jonathan Appelbaum, MD, FACP, AAHIVS, summarizes the many medical challenges faced by aging people with HIV, including:
Underrepresentation of older patients in medical research
Consequences of early experiences in the epidemic such as late HIV diagnosis and low CD4+ cell count nadir, incomplete or short-lived virologic suppression with early regimens, and toxicity associated with early antiretroviral agents
Added challenges of multimorbidity and psychosocial challenges, especially mental health issues, loneliness, and social isolation
The need to provide care for the aging HIV population using a holistic approach
Gaps in the current healthcare system in providing optimal care for aging people with HIV
Faculty:
Jonathan Appelbaum, MD, FACP, AAHIVS Laurie L. Dozier Jr, MD, Education Director Professor of Internal Medicine Chair, Department of Clinical Sciences Florida State University College of Medicine Tallahassee, Florida
Contemporary Management of HIV 2021: Heavily Treatment–Experienced Patients—Audio Recap Part 2
00:11:19
In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from:
BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patients
TMB-301, a study that added the monoclonal antibody ibalizumab in pretreated patients with multidrug-resistant HIV and demonstrated significant decreases in HIV-1 RNA
BRIGHTE, which showed that the addition of fostemsavir in heavily treatment–experienced patients with HIV led to a significant decrease in HIV-1 RNA
VIKING-3, a study that demonstrated the addition of DTG dosed BID in INI-resistant patients was effective in decreasing HIV-1 RNA
SWITCHMRK, a study that showed underlying resistance matters when deciding to switch regimens in a treatment-experienced, virologically suppressed patient, especially when switching to a regimen with a low barrier to resistance
DAWNING, a study that demonstrated that DTG, when added to 2 NRTIs, was superior to RTV-boosted LPV in patients with virologic failure on an NNRTI plus 2 NRTIs
BRAAVE, which evaluated safety and efficacy of switching to BIC/FTC/TAF in Black patients virologically suppressed on 2 NRTIs plus a third agent
In addition, Dr. Gupta reviews current DHHS ART guideline recommendations related to managing virologic failure, including drug resistance testing and drug selection, as well as switching recommendations in patients with viral suppression and underlying drug resistance.
Presenter:
Geeta Gupta, MD Professor Director, AIDS Education and Training Center University of California, Irvine Orange, California
Hepatitis delta virus (HDV) is the most severe form of viral hepatitis, yet many patients go undiagnosed. Increasing HDV awareness is an important step to correct this and ensure that at-risk patients receive screening and then treatment and monitoring following a positive test. Hear Grace LH Wong, MD, and Ming-Lung Yu, MD, PhD, discuss a call to action to increase healthcare professional and patient awareness of HDV.
Presenters:
Grace LH Wong, MD Professor Director, Medical Data Analytics Centre (MDAC) Deputy Director, Center for Liver Health Assistant Dean (Learning Experience), Faculty of Medicine The Chinese University of Hong Kong Honorary Consultant Division of Gastroenterology and Hepatology Department of Medicine and Therapeutics Prince of Wales Hospital Hong Kong
Ming-Lung Yu, MD, PhD Chair Professor Hepatobiliary Division Department of Internal Medicine and Hepatitis Center Kaohsiung Medical University Visiting Staff Hepatobiliary Division Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung City, Taiwan
In this episode, Sonal Kumar, MD, MPH, discusses key findings from primary biliary cholangitis (PBC) studies presented at AASLD 2024, including:
ELATIVE, a phase III trial of elafibranor for PBC
RESPONSE, a phase III trial of seladelpar for PBC
ASSURE, another phase III trial of seladelpar for PBC
Presenter: Sonal Kumar, MD, MPH Director, Clinical Gastroenterology and Hepatology Assistant Professor of Medicine Weill Cornell Medical College New York, New York
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
07 Dec 2022
Addressing ART Safety and Tolerability in Transgender Individuals
00:18:01
In this episode, Jill Blumenthal, MD, MAS, and Jennifer Cocohoba, PharmD, share how they manage possible antiretroviral (ARV)-associated toxicities in transgender individuals, including:
Strategies on how to approach different ARV-related toxicities
Other factors to consider when assessing possible ARV-related toxicities (eg, weight gain, cardiovascular disease), such as gender-affirming care and nonmedication risk factors (eg, smoking, life stressors)
Clinically relevant drug–drug interactions related to HIV and gender-affirming care
Methods to reduce barriers to ART adherence
Faculty:
Jill Blumenthal, MD, MAS Associate Professor of Medicine Infectious Diseases and Global Public Health University of California, San Diego San Diego, California
Jennifer Cocohoba, PharmD Professor Department of Clinical Pharmacy University of California, San Francisco Pharmacist Women’s HIV Program University of California San Francisco Medical Center San Francisco, California
What Patients Want in HIV Treatment and Prevention: United States
00:38:19
In this episode, Deondre Moore and Samantha V. Hill, MD, MPH, discuss some of the barriers to genuinely patient-centered HIV care in the United States and offer calls to action for healthcare professionals for responding to patient preferences. They talk through some of the barriers that patients face, from struggling with unfamiliar medical terminology, to healthcare professional biases, to more structural problems like housing and food scarcity. They also discuss strategies that healthcare professionals can incorporate to provide more comprehensive, inclusive, collaborative HIV care.
Samantha V. Hill, MD, MPH Assistant Professor Division of Adolescent Medicine Department of Pediatrics The University of Alabama at Birmingham Birmingham, Alabama
Deondre Moore U.S. Partnerships and Community Engagement Manager Prevention Access Campaign Houston, Texas
HIV-ASSIST: A Free, Online Tool for Individualized, Evidence-Based ART Selection—Audio Recap
00:42:29
In this episode, Ethel D. Weld, MD, PhD, demonstrates the use of HIV-ASSIST, a free, online, decision support tool to inform ART selection.
Ethel D. Weld, MD, PhD Assistant Professor of Medicine, Pharmacology, & Molecular Sciences Division of Clinical Pharmacology Department of Infectious Diseases Johns Hopkins University School of Medicine Attending Physician Inpatient HIV Service General Infectious Diseases Consult Services Johns Hopkins Hospital Baltimore, Maryland
Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Theratechnologies; and ViiV Healthcare.
Lessons From Lockdown: Hepatitis Delta Elimination Strategies in the COVID-19 Era
00:29:44
In this episode, Robert G. Gish, MD, and Pietro Lampertico, MD, PhD, share lessons learned in the care of patients coinfected with hepatitis B virus and hepatitis delta virus (HDV), including:
Burden of HDV infection
Chronic HDV infection and comorbidities
Impact of COVID-19 on care of patients with chronic hepatitis B
Screening for HDV and which assays to use
Screening for viral hepatitis at a COVID-19 vaccination site
Presenters:
Robert G. Gish, MD, FAASLD, AGAF, FAST Professor of Medicine Loma Linda University Loma Linda, California Clinical Professor University of Nevada Reno School of Medicine Reno, Nevada University of California Skaggs School of Pharmacy and Pharmaceutical Sciences San Diego, California Medical Director Hepatitis B Foundation Washington, DC
Pietro Lampertico, MD, PhD Professor of Gastroenterology Director, Division of Gastroenterology and Hepatology IRCCS Ca Granda Policlinico Hospital University of Milan Milan, Italy
Studies of LA ART in People With Adherence Challenges or Viremia
00:09:36
In this episode, Jonathan Appelbaum, MD, FACP, AAHIVS, discusses the newest data supporting LA ART use in people with adherence challenges or viremia, including:
The LATITUDE study, an open-label phase III study of LA CAB + RPV in people with a suboptimal response or nonadherence to oral ART
Updates to the Ward 86 cohort, which showed 81% of patients with viral suppression on LA CAB + RPV at Week 48
The CARES study, an open-label, noninferiority phase IIIb study of LA CAB + RPV in people with baseline resistance mutations
Presenter:
Jonathan Appelbaum, MD, FACP, AAHIVS Laurie L. Dozier, Jr., MD Education Director and Professor of Internal Medicine Chair, Department of Clinical Sciences Florida State University College of Medicine Medical Director Care Point Health and Wellness Tallahassee, Florida
To get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.
25 Sep 2020
COVID-19: Answering the Questions, Part 7
00:33:49
In this episode, Part 7 of an ongoing 12-part COVID-19 series, Leo Yee-Sin, MBBS, MPH, MRCP, FRCP, FAMS, provides a brief update on COVID-19 risk and prevention strategies among healthcare workers. After the update, Professor Leo answers clinician questions on various aspects of COVID-19.
Presenter:
Leo Yee-Sin, MBBS, MPH, MRCP, FRCP, FAMS
Professor Lee Kong Chian School of Medicine Saw Swee Hock School of Public Health Nanyang Technological University National University of Singapore Senior Consultant National Centre for Infectious Disease Singapore
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Beyond Viral Suppression: A Case Study Addressing Internalized HIV Stigma
00:12:29
In this episode, Gregory Huhn, MD, MPHTM, uses a case study to explore the reasons healthcare professionals and people living with HIV may want to further optimize ART in the setting of viral suppression.
To determine the best outcome for this case study, Dr Huhn discusses the reasons individuals may not be satisfied with daily oral ART and examines data to suggest that, for some individuals with virologic suppression, switching to long-acting ART may address internalized HIV stigma.
Finally, Dr Huhn takes a look at the optimal candidates for switching to a long-acting ART regimen and settings where proviral DNA genotyping may be considered prior to switching.
Presenter:
Gregory Huhn, MD, MPHTM Interim Chief, Division of Infectious Diseases Senior Director of HIV Services Cook County HIV Integrated Programs Interim Medical Director, The RMR CORE Center Professor, Division of Infectious Diseases Rush University Medical Center Chicago, Illinois
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Améliorez votre compréhension de CCO Infectious Disease Podcast avec My Podcast Data
Chez My Podcast Data, nous nous efforçons de fournir des analyses approfondies et basées sur des données tangibles. Que vous soyez auditeur passionné, créateur de podcast ou un annonceur, les statistiques et analyses détaillées que nous proposons peuvent vous aider à mieux comprendre les performances et les tendances de CCO Infectious Disease Podcast. De la fréquence des épisodes aux liens partagés en passant par la santé des flux RSS, notre objectif est de vous fournir les connaissances dont vous avez besoin pour vous tenir à jour. Explorez plus d'émissions et découvrez les données qui font avancer l'industrie du podcast.
